ClearSight Labs opened as the first cannabis testing laboratory in the nation’s capital, roughly a decade after the launch of Washington, DC’s medical cannabis program. Its arrival filled a major gap in the local safety system by giving the District an independent laboratory capable of analyzing cannabis products before they reached patients.
Patients rely on testing to understand what a product contains and whether it meets basic expectations for potency, contaminants, and other quality measures. Without independent laboratory analysis, the information available to patients is only as strong as the claims made by producers and sellers.
ClearSight Labs sees testing as more than a compliance exercise. Its goal is to provide information patients can use to make educated decisions, recognizing that laboratory data are most valuable when people can understand what the results mean and apply them to product choices.
That combination of independent analysis and patient-facing information gives ClearSight a distinct role in Washington, DC’s medical cannabis infrastructure. The laboratory is helping establish a system in which product claims can be checked, safety information can be verified, and patients can make decisions with greater confidence.
ClearSight Labs embodies the Full Disclosure Award by helping move cannabis product information from assertion to verification. Its work gives patients access to independent laboratory results they can use to better understand the products they depend on.
Website: ClearSight Labs
 |
“ClearSight Labs is honored to be nominated and recognized for our role in advancing cannabis safety in Washington D.C. We strive to set the standard for cannabis testing and work hard to deliver the insights patients need to make educated decisions.” |
Support ClearSight Labs for the 2026 Full Disclosure Award
If you appreciate ASA's work, sign up for alerts and updates, and make a donation to support ASA's vital mission.
Share this page
